Bexobrutideg (NX-5948)

May 12, 2026 — Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that an abstract with updated efficacy and safety results from its ongoing Phase 1a/b trial of the BTK degrader bexobrutideg (NX-5948) in chronic lymphocytic leukemia (CLL) patients “across lines of therapy” has been accepted for an oral presentation at the 31st European Hematology Association Congress (EHA2026; June 11–14, 2026, Stockholm).

The oral presentation (“Updated efficacy and safety data from an ongoing phase 1a/b trial…”) will be delivered by Tahla Munir, MBChB, PhD, in the “Novel therapies in relapsed/refractory CLL” session on June 14, 2026 (Abstract ID S150).

Nurix describes bexobrutideg as an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule BTK degrader. The release also notes ongoing evaluation in the DAYBreak CLL-201 pivotal single-arm Phase 2 study in relapsed/refractory CLL and continued enrollment in the NX-5948-301 Phase 1a/1b study in relapsed/refractory B-cell malignancies.